SusanD.WyrickMD

PubMed

• The synthesis of homophthalimide and related derivatives and their hypolipidemic activity in rodents.
  Murthy AR, Chapman JM, Wyrick SD, Hall IH> ;Pharm. Res.. 1986-10-01
• The Hypolipidemic Activity of a Series of 2,3-Dihydrophthalazine-l,4-dione Derivatives in Rodents.
  Murthy AR, Hall IH, Chapman JM, Rhyne KA, Wyrick SD> ;Pharm. Res.. 1986-04-01
• Hypolipidemic Agents of Phthalimide Derivatives 6. Effects of Aromatic vs. Non-Aromatic Imides.
  Chapman JM, Wyrick SD, Maguire JH, Cocolas GH, Hall IH> ;Pharm. Res.. 1984-11-01
• The Hypolipidemic Activity of N-(p-Chlorobenzoyl)-sulfamate in Rodents and its Effect on Lipid Metabolism.
  Hall IH, Wyrick SD, Voorstad PJ, Dubey A> ;Pharm. Res.. 1984-01-01
• In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma.
  Chaney, S. G., Wyrick, S., Till, G. K.> ;Cancer Res. 1990 Aug 1
• Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
  McBain, C. J., Kleckner, N. W., Wyrick, S., Dingledine, R.> ;Mol Pharmacol. 1989 Oct
• Multiple forms of the D1 dopamine receptor: its linkage to adenylate cyclase and psychopharmacological effects.
  Mailman, R. B., Schulz, D. W., Kilts, C. D., Lewis, M. H., Rollema, H., Wyrick, S.> ;Psychopharmacol Bull. 1986
• Compounds that inhibit chymotrypsin and cell replication.
  Goz, B., Ganguli, C., Troconis, M., Wyrick, S., Ishaq, K. S., Katzenellenbogen, J. A.> ;Biochem Pharmacol. 1986 Oct 15
• Structure-activity relationships for binding and inactivation of rabbit reticulocyte ribosomes by quassinoid antineoplastic agents.
  Considine, R. T., Willingham, W., Chaney, S. G., Wyrick, S., Hall, I. H., Lee, K. H.> ;Eur J Biochem. 1983 Apr 15
• Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares...
  Hoffman, B., Cho, S. J., Zheng, W., Wyrick, S., Nichols, D. E., Mailman, R. B., Tropsha, A.> ;J Med Chem. 1999 Aug 26
• The multiplicity of the D1 dopamine receptor.
  Mailman, R. B., Schulz, D. W., Kilts, C. D., Lewis, M. H., Rollema, H., Wyrick, S.> ;Adv Exp Med Biol. 1986
• Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.
  Gibbons, G. R., Wyrick, S., Chaney, S. G.> ;Cancer Res. 1989 Mar 15
• Cellular metabolism in lymphocytes of a novel thioether-phospholipid-AZT conjugate with anti-HIV-1 activity.
  Kucera, G. L., Goff, C. L., Iyer, N., Morris-Natschke, S., Ishaq, K. S., Wyrick, S. D., Fleming, R. A., Kucera, L. S.> ;Antiviral Res. 2001 May
• A novel phenylaminotetralin (PAT) recognizes histamine H1 receptors and stimulates dopamine synthesis in vivo in rat brain.
  Choksi, N. Y., Nix, W. B., Wyrick, S. D., Booth, R. G.> ;Brain Res. 2000 Jan 3
• The disposition of the hypolipidemic agent, o-(N-phthalimido)acetophenone, in Sprague-Dawley rats.
  Hall, I. H., Reynolds, D. J., Wyrick, S. D., Maguire, J. H., Shrewsbury, R. P.> ;Drug Metab Dispos. 1988 Mar 01
• Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
  Bucholtz, E. C., Brown, R. L., Tropsha, A., Booth, R. G., Wyrick, S. D.> ;J Med Chem. 1999 Aug 12
• Putative sigma(3) sites in mammalian brain have histamine H(1) receptor properties: evidence from ligand binding and distribution studies with the novel H(1) radioliga...
  Booth, R. G., Owens, C. E., Brown, R. L., Bucholtz, E. C., Lawler, C. P., Wyrick, S. D.> ;Brain Res. 1999 Aug 7
• Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
  Luo, F. R., Wyrick, S. D., Chaney, S. G.> ;Oncol Res. 1998
• Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.
  Luo, F. R., Wyrick, S. D., Chaney, S. G.> ;Cancer Chemother Pharmacol. 1999
• Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
  Luo, F. R., Wyrick, S. D., Chaney, S. G.> ;Cancer Chemother Pharmacol. 1999
• High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin.
  Luo, F. R., Yen, T. Y., Wyrick, S. D., Chaney, S. G.> ;J Chromatogr B Biomed Sci Appl. 1999 Mar 19
• Biotransformations of oxaliplatin in rat blood in vitro.
  Luo, F. R., Wyrick, S. D., Chaney, S. G.> ;J Biochem Mol Toxicol. 1999
• Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.
  Holmes, J., Stanko, J., Varchenko, M., Ding, H., Madden, V. J., Bagnell, C. R., Wyrick, S. D., Chaney, S. G.> ;Toxicol Sci. 1998 Dec
• Cytoxicity of [(5,6-dichloro-9a-n-propyl-2,3,9,9a-tetrahydro-3-oxo-1H fluoren-7-yl)oxy]acetic acid, an agent known to reduce brain edema.
  Hall, I. H., Wyrick, S. D.> ;Biomed Pharmacother. 1996
• Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
  Mottola, D. M., Laiter, S., Watts, V. J., Tropsha, A., Wyrick, S. D., Nichols, D. E., Mailman, R. B.> ;J Med Chem. 1996 Jan 5
• Join now to see all